Who is sponsoring NCT03250910?

NCT03250910 is sponsored by National Taiwan University Hospital.

What drugs are being tested in NCT03250910?

Interventions in NCT03250910: Sofosbuvir and Velpatasvir, Ribavirin.

What condition does NCT03250910 study?

NCT03250910 studies Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus.

Is NCT03250910 still recruiting?

NCT03250910 is currently completed. Last updated 8 December 2017.

Last reviewed 2017-12-08 · How we verify

NCT03250910

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients

Completed Phase 4 Last updated 8 December 2017

What this trial tests

Phase 4 trial testing Sofosbuvir and Velpatasvir in Hepatitis C Virus Infection, Response to Therapy of in 228 participants. Completed in 31 October 2017.

Timeline

1 August 2016

Primary endpoint
15 July 2017

31 October 2017

Quick facts

Lead sponsor	National Taiwan University Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	228
Start date	1 August 2016
Primary completion	15 July 2017
Estimated completion	31 October 2017
Sites	2 locations across Taiwan

Drugs / interventions tested

Sofosbuvir and Velpatasvir — full drug profile →
Ribavirin — full drug profile →

Conditions studied

Hepatitis C Virus Infection, Response to Therapy of — all drugs for Hepatitis C Virus Infection, Response to Therapy of →
Human Immunodeficiency Virus — all drugs for Human Immunodeficiency Virus →

Sponsor

National Taiwan University Hospital

Who can join

20 and older, any sex, with Hepatitis C Virus Infection, Response to Therapy of or Human Immunodeficiency Virus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Data are limited regarding the effectiveness and safety of generic velpatasvir plus sofosbuvir (VEL/SOF) with or without ribavirin (RBV) for the treatment of hepatitis C virus (HCV) in patients with human immunodeficiency virus (HIV) coinfection. We aim to compare the effectiveness and safety of VEL/SOF with and without RBV for 12 weeks in HIV/HCV-coinfected and HCV-monoinfected patients The antiviral responses and the adverse events (AEs) are compare between the two groups. The characteristics potentially related to sustained virologic response 12 weeks off therapy (SVR12) are analyzed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sofosbuvir and Velpatasvir

Trials testing the same drug.

NCT03818308 — Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir · Phase 2 · completed

Other recruiting trials for Hepatitis C Virus Infection, Response to Therapy of

Currently open trials in the same condition.

NCT05361603 — Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures · recruiting

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03250910 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 8 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03250910.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing